VCBeat Health Contact Us
Home Pfizer's Talzenna Plus Xtandi Achieves Landmark Success in Phase III TALAPRO-3 Trial, Setting a New Standard for HRR-Mutated mCSPC Treatment

Pfizer's Talzenna Plus Xtandi Achieves Landmark Success in Phase III TALAPRO-3 Trial, Setting a New Standard for HRR-Mutated mCSPC Treatment

May 31, 2026 11:28 CST Updated 11:28
Johnson & Johnson

Medical Device R&D and Manufacturer

ImageOn May 30, 2026, the American Society of Clinical Oncology (ASCO) Annual Meeting announced a landmark milestone achievement in the field of prostate cancer. Pfizer disclosed its PARP inhibitorTalzenna (talazoparib) in combination with Xtandi (enzalutamide)Positive Key Data from the Phase III Talapro-3 Study in Treating Metastatic Castration-Sensitive Prostate Cancer (mCSPC) with HRR Mutations.
Clinical results confirmed that the combination regimen significantly reduced the risk of radiographic progression or death by 52%, and achievedConsistent Benefit Observed in the Subgroup with Mutations Across the Full Spectrum of HRR Genes, creating an overwhelming advantage over Johnson & Johnson’s Akeega with its narrow-spectrum indications, and is poised to reshape the landscape of first-line precision therapy for metastatic castration-sensitive prostate cancer (mCSPC) globally.

Stellar Core Clinical Data: Benefits Across the Entire Population, with a 21-Percentage-Point Increase in the 3-Year Progression-Free Rate

Talapro-3 is a high-standard, global, multicenter, randomized controlled Phase III clinical trial specifically focused on patients with metastatic hormone-sensitive prostate cancer (mHSPC) harboring homologous recombination repair (HRR) gene mutations. The study results were simultaneously published in the New England Journal of Medicine, demonstrating breakthrough and significant core efficacy data, as detailed below:
  • The experimental group (Talzenna + Xtandi) enabled patients52% Reduction in Risk of Radiographic Progression or Death
  • 3-Year Radiographic Progression-Free Survival (rPFS) Rate Reached77%, significantly higher than the 56% in the Xtandi monotherapy control group
  • Although the overall survival (OS) data are not yet mature, a clear trend toward benefit has been observed, with a 23% reduction in the risk of death; the 3-year OS rates were78% vs 72%
Dr. Jeff Legos, Pfizer’s Chief Oncology Officer, stated: “The Talzenna and Xtandi combination regimen demonstrates consistent and superior antitumor benefits across patients with various HRR gene mutations, holding the promise to fundamentally transform current clinical treatment paradigms, prolong progression-free survival for patients with high-risk prostate cancer, and significantly enhance the potential for clinical cure.”

Overwhelming Advantage: Broad-Spectrum HRR Benefit Outperforms Johnson & Johnson’s Akeega

The core industry value of this study lies in achieving comprehensive superiority over Johnson & Johnson’s benchmark therapy, Akeega. Previously, although Johnson & Johnson’s combination therapy of niraparib plus abiraterone (Akeega) was approved for the metastatic castration-sensitive prostate cancer (mCSPC) indication, its clinical application was significantly limited, failing to meet the treatment needs of a broad patient population:
  • Limited Overall Efficacy: Data from the Amplitude study show that Akeega reduces the risk of radiographic progression by only 37% in patients, indicating modest overall benefit.
  • Highly Limited Benefit: Efficacy was confined to the BRCA2 mutation subgroup (54% risk reduction),Patients with non-BRCA mutations, who constitute a higher proportion, derived almost no significant benefit (only 12%).
  • Narrow Indications: Based on limited clinical benefit data, the FDA has approved it only for patients with BRCA2 mutations, resulting in an extremely limited target population.
In comparison, Pfizer’s Talzenna-based combination regimen thoroughly breaks through the subtype-specific benefit limitations of PARP inhibitors, demonstrating potent and consistent antitumor activity across all HRR mutation subgroups, thereby achieving precise therapeutic benefits for the entire patient population:
  • BRCA Mutation Subgroup: Reduced Risk of Disease Progression63%
  • Non-BRCA Mutation Subgroup: Reduced risk of disease progression43%
  • CDK12 Mutation Subgroup: Highest peak benefit, significantly reduced risk of disease progression72%
  • ATM Mutation Subgroup: Risk Reduction57%
This broad-spectrum benefit advantage, offering comprehensive coverage with no gaps, enables the Talzenna combination regimen to suit a significantly larger patient population than Johnson & Johnson’s Akeega, demonstrating greater clinical applicability and stronger commercial potential.

Safety is manageable: Anemia is the primary adverse reaction, with a low discontinuation rate.

Safety evaluation demonstrated that the Talzenna plus Xtandi regimen was generally well tolerated, with no new or unknown safety risks identified. The most common grade ≥3 treatment-related adverse event observed in the trial was anemia, with an incidence of 51% in the experimental group versus 3% in the control group. Severe anemia was highly manageable, and only 5% of patients discontinued Talzenna due to anemia-related adverse events, indicating a very low overall risk of treatment discontinuation.
Pfizer’s official interpretation states that anemia is a classic, well-known adverse reaction associated with the PARP inhibitor class. In clinical practice, it can be effectively managed through routine measures such as flexible dose adjustments and symptomatic supportive care, without compromising the overall treatment course or patients’ core survival benefits. Its safety profile fully meets the standards for long-term clinical application.

Industry Significance: Advancing Precision Treatment for Prostate Cancer

Prostate cancer is a highly prevalent malignancy among men worldwide, ranking as the second most common cancer in males. The latest 2026 data from the United States estimates approximately 330,000 new cases of prostate cancer annually, with 5%-10% of initially diagnosed patients presenting with metastatic castration-sensitive prostate cancer; among these high-risk patients,Approximately 30% are associated with HRR gene mutations., there is a significant unmet need for precision therapy.
The breakthrough results from the Talapro-3 study further solidify the pivotal upfront role of HRR gene testing in the precision treatment of metastatic prostate cancer. Currently, the global landscape for innovative therapies in metastatic castration-sensitive prostate cancer (mCSPC) is undergoing intensive iteration, with the competitive environment continuing to heat up:
  • AstraZeneca’s Truqap in Combination with Abiraterone Receives Support from FDA Advisory Committee for PTEN-Deficient mCSPC
  • Novartis’ Radioligand Therapy Pluvicto Combined with Standard of Care Reduces Risk of Progression by 28% in PSMA-Positive Patients
Industry analysis indicates that, leveraging its core advantages of benefit across the full spectrum of HRR mutations and significantly superior efficacy compared to existing benchmark therapies, the Talzenna-based combination regimen is poised to rapidly become the preferred first-line treatment option for patients with HRR-mutated metastatic castration-sensitive prostate cancer (mCSPC), thereby further consolidating Pfizer’s leading position in the field of urologic oncology. Meanwhile, this study will further drive the upgrading of the prostate cancer diagnosis and treatment system, accelerating the widespread adoption of the standardized clinical model of “genetic testing first, followed by precision targeted therapy,” enabling more patients with high-risk mutations to overcome the limitations of traditional treatments and achieve superior survival benefits.

References:https://www.fiercepharma.com/pharma/pfizer-one-ups-jj-talzenna-combo-claims-broad-castration-sensitive-prostate-cancer-win

Image